Lipocine Inc Common (LPCN) 3.34 $LPCN
IMPORTANT INVESTOR NOTICE: Khang & Khang LLP Announces the Filing of a Securities Class Action Lawsuit Against Lipocine Inc. and Reminds Investors With Losses to Contact the Firm
BusinessWire - Sat Jul 09, 5:40PM CDT
Khang & Khang LLP (the "Firm"
announces that a class action lawsuit has been filed against Lipocine Inc. ("Lipocine" or the "Company" (Nasdaq:LPCN). Investors who purchased or otherwise acquired shares between June 30, 2015 and June 28, 2016 inclusive (the "Class Period" , are encouraged to contact the Firm prior to the August 30, 2016 lead plaintiff motion deadline.
LPCN: 3.34 (+0.07)
IMPORTANT LIPOCINE, INC. SHAREHOLDER ALERT: Wolf Haldenstein Adler Freeman & Herz LLP Reminds Investors That a Class Action Lawsuit Has Been Commenced on Behalf of Shareholders of Lipocine, Inc.
ACCESSWIRE - Fri Jul 08, 4:52PM CDT
Lead Plaintiff Deadline Is August 30, 2016
LPCN: 3.34 (+0.07)
SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action against Lipocine, Inc. (LPCN) and Lead Plaintiff Deadline August 30, 2016
ACCESSWIRE - Fri Jul 08, 9:25AM CDT
NEW YORK, NY / ACCESSWIRE / July 8, 2016 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Lipocine, Inc. ("Lipocine" or the "Company" (NASDAQ: LPCN) and certain of its officers. The class action was filed on behalf of a class consisting of all persons or entities who purchased Lipocine securities between June 30, 2015 through June 28, 2016, both dates inclusive (the "Class Period" .
LPCN: 3.34 (+0.07)
INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against Lipocine Inc. And Reminds Investors With Losses To Contact The Firm
BusinessWire - Thu Jul 07, 6:24PM CDT
Lundin Law PC announces a class action lawsuit has been filed against Lipocine Inc. ("Lipocine" or the "Company" (Nasdaq: LPCN) concerning possible violations of federal securities laws between June 30, 2015 and June 28, 2016 (the "Class Period" . Investors who purchased or otherwise acquired shares during the Class Period should contact the Firm in advance of the August 30, 2016 lead plaintiff motion deadline.
LPCN: 3.34 (+0.07)
Glancy Prongay & Murray LLP Files Securities Class Action Lawsuit Against Lipocine Inc.
BusinessWire - Thu Jul 07, 3:41PM CDT
Glancy Prongay & Murray LLP ("GPM" announces that it has filed a class action lawsuit in the United States District Court for the District of New Jersey on behalf of a class (the "Class" of individuals who purchased Lipocine Inc. ("Lipocine" or the "Company" (NASDAQ: LPCN) securities between February 27, 2015 and June 28, 2016, inclusive (the "Class Period" .
LPCN: 3.34 (+0.07)
Lipocine Inc. Shareholder Alert: Former SEC Attorney Willie Briscoe and Powers Taylor Investigate Possible Breaches of Fiduciary Duty by Officers and Directors
BusinessWire - Thu Jul 07, 12:53PM CDT
Former United States Securities and Exchange Commission attorney Willie Briscoe, founder of The Briscoe Law Firm, PLLC, and the securities litigation firm of Powers Taylor LLP announce that a federal class action lawsuit has been filed against Lipocine Inc. ("Lipocine" (NASDAQ: LPCN) and several officers and directors for acts taken during the period of June 30, 2015 to June 28, 2016 (the "Class Period" .
LPCN: 3.34 (+0.07)
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Lipocine Inc. and Certain Officers - LPCN
GlobeNewswire - Wed Jul 06, 3:40PM CDT
Pomerantz LLP announces that a class action lawsuit has been filed against Lipocine Inc. ("Lipocine" or the "Company" (NASDAQ:LPCN), and certain of the company's officers. The class action, filed in United States District Court, District of New Jersey, is on behalf of a class consisting of all persons other than Defendants who purchased or acquired Lipocine securities between June 30, 2015 and June 28, 2016, both dates inclusive (collectively, the "Class Period" , seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act" and Rule 10b-5 promulgated thereunder.
LPCN: 3.34 (+0.07)
Robbins Arroyo LLP: Lipocine, Inc. (LPCN) Misled Shareholders According to a Recently Filed Class Action
BusinessWire - Wed Jul 06, 3:33PM CDT
Shareholder rights law firm Robbins Arroyo LLP announces that a class action complaint was filed against Lipocine, Inc. (NASDAQCM: LPCN) in the U.S. District Court for the District of New Jersey. The complaint is brought on behalf of all purchasers of Lipocine securities between June 30, 2015 and June 28, 2016, for alleged violations of the Securities Exchange Act of 1934 by Lipocine's officers and directors. Lipocine, a specialty pharmaceutical company, develops pharmaceutical products using its oral drug delivery technology in the areas of men's and women's health. The company's lead product candidate, TLANDO ("LPCN 1021" is an oral testosterone replacement therapy designed for twice-a-day dosing.
LPCN: 3.34 (+0.07)
INVESTOR ALERT: Investigation of Lipocine Inc. Announced by Law Offices of Howard G. Smith
BusinessWire - Wed Jul 06, 9:30AM CDT
Law Offices of Howard G. Smith announces an investigation on behalf of investors of Lipocine Inc. ("Lipocine" or the "Company" (NASDAQ: LPCN) concerning the Company and its officers' possible violations of federal securities laws.
LPCN: 3.34 (+0.07)
EQUITY ALERT: Rosen Law Firm Files Securities Class Action Against Lipocine Inc. - LPCN
BusinessWire - Fri Jul 01, 4:00PM CDT
Rosen Law Firm, a global investor rights law firm, announces that it has filed a class action lawsuit on behalf of purchasers of Lipocine Inc. securities (NASDAQ: LPCN) from June 30, 2015 through June 28, 2016, inclusive (the "Class Period" . The lawsuit seeks to recover damages for Lipocine investors under the federal securities laws.
LPCN: 3.34 (+0.07)
IMPORTANT INVESTOR NOTICE: Lundin Law PC Announces Investigation Of Lipocine, Inc. And Advises Investors With Losses to Contact the Firm
BusinessWire - Wed Jun 29, 3:59PM CDT
Lundin Law PC announces it is investigating claims against Lipocine, Inc. ("Lipocine" or the "Company" (Nasdaq: LPCN) concerning possible violations of federal securities laws. The investigation is related to allegations that certain statements issued by Lipocine were false and misleading and/or failed to disclose material information regarding the Company's financial performance.
LPCN: 3.34 (+0.07)
Lipocine reports 1Q loss
Automated Insights - Mon May 09, 3:47PM CDT
SALT LAKE CITY (AP) _ Lipocine Inc. (LPCN) on Monday reported a loss of $7 million in its first quarter.
LPCN: 3.34 (+0.07)
Lipocine Announces the Presentation of Clinical Data for Oral Testosterone Replacement Therapy Product Candidate TLANDO(TM) ("LPCN 1021" at the 2016 American Urological Association Annual Meeting
GlobeNewswire - Mon May 02, 7:00AM CDT
Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that clinical data for lead candidate TLANDO(TM) ("LPCN 1021" , will be presented in poster and podium presentations at the 2016 American Urological Association Annual Meeting being held May 6-10 in San Diego, CA. TLANDO is an oral testosterone replacement therapy ("TRT" product candidate being developed for adult males with conditions associated with a deficiency or absence of endogenous testosterone, also known as hypogonadism.
LPCN: 3.34 (+0.07)
Impending PDUFA Dates Offer Opportunity for Large Move in Pharmaceutical Companies
ACCESSWIRE - Tue Apr 12, 7:46AM CDT
NEW YORK, NY / ACCESSWIRE / April 12, 2016 / Chiasma, Inc. (NASDAQ: CHMA), KemPharm, Inc. (NASDAQ: KMPH), Lipocine Inc. (NASDAQ: LPCN), and Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) have PDUFA dates scheduled over the next couple of months which could significantly alter the prospects for the companies.
KMPH: 4.29 (+0.16), VNDA: 11.47 (+0.02), LPCN: 3.34 (+0.07), CHMA: 2.98 (+0.10)
Lipocine Announces the Presentation of Clinical Data for LPCN 1021, Its Oral Testosterone Replacement Therapy Product Candidate, at ENDO 2016
GlobeNewswire - Mon Mar 28, 7:30AM CDT
Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that clinical data for LPCN 1021, an oral testosterone replacement therapy ("TRT" product candidate being developed for adult males with conditions associated with a deficiency or absence of endogenous testosterone, also known as hypogonadism, will be presented at ENDO 2016 in Boston, MA.
LPCN: 3.34 (+0.07)
Lipocine Announces the Presentation of Clinical Data for LPCN 1021, Its Oral Testosterone Replacement Therapy Product Candidate, at the American Society of Andrology 41st Annual Conference
GlobeNewswire - Mon Mar 28, 7:30AM CDT
Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that clinical data for LPCN 1021, an oral testosterone replacement therapy ("TRT" product candidate being developed for adult males with conditions associated with a deficiency or absence of endogenous testosterone, also known as hypogonadism, will be presented at the American Society of Andrology 41 Annual Meeting in New Orleans, LA.
LPCN: 3.34 (+0.07)
Lipocine Announces Financial and Operational Results for the Full Year of 2015
GlobeNewswire - Thu Mar 10, 3:30PM CST
Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced financial results for the full year ended December 31, 2015.
LPCN: 3.34 (+0.07)
Lipocine to Present at 28th Annual Roth Conference
GlobeNewswire - Tue Mar 08, 7:00AM CST
Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that Mahesh Patel, President and CEO, and Morgan Brown, Executive Vice President and CFO, will present a company overview at the 28 Annual Roth Conference on Tuesday, March 15, 2016 at 8:00 a.m. PT.
LPCN: 3.34 (+0.07)
Labor and Delivery Global Clinical Trials Review, H2, 2015 - Key Vendors: Lipocine Inc., Alliance Pharma Plc & Christiana Care Health System - Research and Markets
BusinessWire - Tue Jan 19, 5:53AM CST
Research and Markets (http://www.researchandmarkets.com/research/2l5cl9/labor_and) has announced the addition of the "Labor And Delivery Global Clinical Trials Review, H2, 2015" report to their offering.
LPCN: 3.34 (+0.07)
IMPORTANT INVESTOR NOTICE: Khang & Khang LLP Announces the Filing of a Securities Class Action Lawsuit Against Lipocine Inc. and Reminds Investors With Losses to Contact the Firm
BusinessWire - Sat Jul 09, 5:40PM CDT
Khang & Khang LLP (the "Firm"
announces that a class action lawsuit has been filed against Lipocine Inc. ("Lipocine" or the "Company" (Nasdaq:LPCN). Investors who purchased or otherwise acquired shares between June 30, 2015 and June 28, 2016 inclusive (the "Class Period" , are encouraged to contact the Firm prior to the August 30, 2016 lead plaintiff motion deadline. LPCN: 3.34 (+0.07)
IMPORTANT LIPOCINE, INC. SHAREHOLDER ALERT: Wolf Haldenstein Adler Freeman & Herz LLP Reminds Investors That a Class Action Lawsuit Has Been Commenced on Behalf of Shareholders of Lipocine, Inc.
ACCESSWIRE - Fri Jul 08, 4:52PM CDT
Lead Plaintiff Deadline Is August 30, 2016
LPCN: 3.34 (+0.07)
SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action against Lipocine, Inc. (LPCN) and Lead Plaintiff Deadline August 30, 2016
ACCESSWIRE - Fri Jul 08, 9:25AM CDT
NEW YORK, NY / ACCESSWIRE / July 8, 2016 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Lipocine, Inc. ("Lipocine" or the "Company"
(NASDAQ: LPCN) and certain of its officers. The class action was filed on behalf of a class consisting of all persons or entities who purchased Lipocine securities between June 30, 2015 through June 28, 2016, both dates inclusive (the "Class Period" . LPCN: 3.34 (+0.07)
INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against Lipocine Inc. And Reminds Investors With Losses To Contact The Firm
BusinessWire - Thu Jul 07, 6:24PM CDT
Lundin Law PC announces a class action lawsuit has been filed against Lipocine Inc. ("Lipocine" or the "Company"
(Nasdaq: LPCN) concerning possible violations of federal securities laws between June 30, 2015 and June 28, 2016 (the "Class Period" . Investors who purchased or otherwise acquired shares during the Class Period should contact the Firm in advance of the August 30, 2016 lead plaintiff motion deadline. LPCN: 3.34 (+0.07)
Glancy Prongay & Murray LLP Files Securities Class Action Lawsuit Against Lipocine Inc.
BusinessWire - Thu Jul 07, 3:41PM CDT
Glancy Prongay & Murray LLP ("GPM"
announces that it has filed a class action lawsuit in the United States District Court for the District of New Jersey on behalf of a class (the "Class" of individuals who purchased Lipocine Inc. ("Lipocine" or the "Company" (NASDAQ: LPCN) securities between February 27, 2015 and June 28, 2016, inclusive (the "Class Period" . LPCN: 3.34 (+0.07)
Lipocine Inc. Shareholder Alert: Former SEC Attorney Willie Briscoe and Powers Taylor Investigate Possible Breaches of Fiduciary Duty by Officers and Directors
BusinessWire - Thu Jul 07, 12:53PM CDT
Former United States Securities and Exchange Commission attorney Willie Briscoe, founder of The Briscoe Law Firm, PLLC, and the securities litigation firm of Powers Taylor LLP announce that a federal class action lawsuit has been filed against Lipocine Inc. ("Lipocine"
(NASDAQ: LPCN) and several officers and directors for acts taken during the period of June 30, 2015 to June 28, 2016 (the "Class Period" . LPCN: 3.34 (+0.07)
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Lipocine Inc. and Certain Officers - LPCN
GlobeNewswire - Wed Jul 06, 3:40PM CDT
Pomerantz LLP announces that a class action lawsuit has been filed against Lipocine Inc. ("Lipocine" or the "Company"
(NASDAQ:LPCN), and certain of the company's officers. The class action, filed in United States District Court, District of New Jersey, is on behalf of a class consisting of all persons other than Defendants who purchased or acquired Lipocine securities between June 30, 2015 and June 28, 2016, both dates inclusive (collectively, the "Class Period" , seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act" and Rule 10b-5 promulgated thereunder. LPCN: 3.34 (+0.07)
Robbins Arroyo LLP: Lipocine, Inc. (LPCN) Misled Shareholders According to a Recently Filed Class Action
BusinessWire - Wed Jul 06, 3:33PM CDT
Shareholder rights law firm Robbins Arroyo LLP announces that a class action complaint was filed against Lipocine, Inc. (NASDAQCM: LPCN) in the U.S. District Court for the District of New Jersey. The complaint is brought on behalf of all purchasers of Lipocine securities between June 30, 2015 and June 28, 2016, for alleged violations of the Securities Exchange Act of 1934 by Lipocine's officers and directors. Lipocine, a specialty pharmaceutical company, develops pharmaceutical products using its oral drug delivery technology in the areas of men's and women's health. The company's lead product candidate, TLANDO ("LPCN 1021"
is an oral testosterone replacement therapy designed for twice-a-day dosing. LPCN: 3.34 (+0.07)
INVESTOR ALERT: Investigation of Lipocine Inc. Announced by Law Offices of Howard G. Smith
BusinessWire - Wed Jul 06, 9:30AM CDT
Law Offices of Howard G. Smith announces an investigation on behalf of investors of Lipocine Inc. ("Lipocine" or the "Company"
(NASDAQ: LPCN) concerning the Company and its officers' possible violations of federal securities laws. LPCN: 3.34 (+0.07)
EQUITY ALERT: Rosen Law Firm Files Securities Class Action Against Lipocine Inc. - LPCN
BusinessWire - Fri Jul 01, 4:00PM CDT
Rosen Law Firm, a global investor rights law firm, announces that it has filed a class action lawsuit on behalf of purchasers of Lipocine Inc. securities (NASDAQ: LPCN) from June 30, 2015 through June 28, 2016, inclusive (the "Class Period"
. The lawsuit seeks to recover damages for Lipocine investors under the federal securities laws. LPCN: 3.34 (+0.07)
IMPORTANT INVESTOR NOTICE: Lundin Law PC Announces Investigation Of Lipocine, Inc. And Advises Investors With Losses to Contact the Firm
BusinessWire - Wed Jun 29, 3:59PM CDT
Lundin Law PC announces it is investigating claims against Lipocine, Inc. ("Lipocine" or the "Company"
(Nasdaq: LPCN) concerning possible violations of federal securities laws. The investigation is related to allegations that certain statements issued by Lipocine were false and misleading and/or failed to disclose material information regarding the Company's financial performance. LPCN: 3.34 (+0.07)
Lipocine reports 1Q loss
Automated Insights - Mon May 09, 3:47PM CDT
SALT LAKE CITY (AP) _ Lipocine Inc. (LPCN) on Monday reported a loss of $7 million in its first quarter.
LPCN: 3.34 (+0.07)
Lipocine Announces the Presentation of Clinical Data for Oral Testosterone Replacement Therapy Product Candidate TLANDO(TM) ("LPCN 1021"
at the 2016 American Urological Association Annual Meeting GlobeNewswire - Mon May 02, 7:00AM CDT
Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that clinical data for lead candidate TLANDO(TM) ("LPCN 1021"
, will be presented in poster and podium presentations at the 2016 American Urological Association Annual Meeting being held May 6-10 in San Diego, CA. TLANDO is an oral testosterone replacement therapy ("TRT" product candidate being developed for adult males with conditions associated with a deficiency or absence of endogenous testosterone, also known as hypogonadism. LPCN: 3.34 (+0.07)
Impending PDUFA Dates Offer Opportunity for Large Move in Pharmaceutical Companies
ACCESSWIRE - Tue Apr 12, 7:46AM CDT
NEW YORK, NY / ACCESSWIRE / April 12, 2016 / Chiasma, Inc. (NASDAQ: CHMA), KemPharm, Inc. (NASDAQ: KMPH), Lipocine Inc. (NASDAQ: LPCN), and Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) have PDUFA dates scheduled over the next couple of months which could significantly alter the prospects for the companies.
KMPH: 4.29 (+0.16), VNDA: 11.47 (+0.02), LPCN: 3.34 (+0.07), CHMA: 2.98 (+0.10)
Lipocine Announces the Presentation of Clinical Data for LPCN 1021, Its Oral Testosterone Replacement Therapy Product Candidate, at ENDO 2016
GlobeNewswire - Mon Mar 28, 7:30AM CDT
Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that clinical data for LPCN 1021, an oral testosterone replacement therapy ("TRT"
product candidate being developed for adult males with conditions associated with a deficiency or absence of endogenous testosterone, also known as hypogonadism, will be presented at ENDO 2016 in Boston, MA. LPCN: 3.34 (+0.07)
Lipocine Announces the Presentation of Clinical Data for LPCN 1021, Its Oral Testosterone Replacement Therapy Product Candidate, at the American Society of Andrology 41st Annual Conference
GlobeNewswire - Mon Mar 28, 7:30AM CDT
Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that clinical data for LPCN 1021, an oral testosterone replacement therapy ("TRT"
product candidate being developed for adult males with conditions associated with a deficiency or absence of endogenous testosterone, also known as hypogonadism, will be presented at the American Society of Andrology 41 Annual Meeting in New Orleans, LA. LPCN: 3.34 (+0.07)
Lipocine Announces Financial and Operational Results for the Full Year of 2015
GlobeNewswire - Thu Mar 10, 3:30PM CST
Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced financial results for the full year ended December 31, 2015.
LPCN: 3.34 (+0.07)
Lipocine to Present at 28th Annual Roth Conference
GlobeNewswire - Tue Mar 08, 7:00AM CST
Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that Mahesh Patel, President and CEO, and Morgan Brown, Executive Vice President and CFO, will present a company overview at the 28 Annual Roth Conference on Tuesday, March 15, 2016 at 8:00 a.m. PT.
LPCN: 3.34 (+0.07)
Labor and Delivery Global Clinical Trials Review, H2, 2015 - Key Vendors: Lipocine Inc., Alliance Pharma Plc & Christiana Care Health System - Research and Markets
BusinessWire - Tue Jan 19, 5:53AM CST
Research and Markets (http://www.researchandmarkets.com/research/2l5cl9/labor_and) has announced the addition of the "Labor And Delivery Global Clinical Trials Review, H2, 2015" report to their offering.
LPCN: 3.34 (+0.07)
